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Abstract
Several members of the NLR family of sensors activate innate immunity. In contrast, we found
here that NLRC3 inhibited Toll-like receptor (TLR)-dependent activation of the transcription
factor NF-κB by interacting with the TLR signaling adaptor TRAF6 to attenuate Lys63 (K63)-
linked ubiquitination of TRAF6 and activation of NF-κB. We used bioinformatics to predict
interactions between NLR and TRAF proteins, including interactions of TRAF with NLRC3. In
vivo, macrophage expression of Nlrc3 mRNA was diminished by the administration of
lipopolysaccharide (LPS) but was restored when cellular activation subsided. To assess biologic
relevance, we generated Nlrc3−/− mice. LPS-treated Nlrc3−/− macrophages had more K63-
ubiquitinated TRAF6, nuclear NF-κB and proinflammatory cytokines. Finally, LPS-treated
Nlrc3−/− mice had more signs of inflammation. Thus, signaling via NLRC3 and TLR constitutes a
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negative feedback loop. Furthermore, prevalent NLR-TRAF interactions suggest the formation of
a ‘TRAFasome’ complex.
The NLR (nucleotide-binding, leucine-rich repeat–containing) family of sensors has many
functions, including inflammatory and anti-inflammatory roles. This group is defined by a
conserved structure composed of a nucleotide-binding domain (NBD), a variable number of
leucine-rich repeats and an amino-terminal effector domain, commonly a pyrin domain or a
caspase-recruitment domain1. The most commonly studied subgroup of NLR proteins is
composed of the inflammasome-forming NLR proteins. NLRP1, NLRP2, NLRP3, NLRC4,
NLRC5, NLRP6 and NLRP7 are each able to form an inflammasome complex, which leads
to the processing and activation of pro-caspase-1 to caspase-1, all of which can occur with
or without the adaptor ASC (PYCARD), depending on the NLR and the experimental
conditions1–6. The inflammasome responds to a wide array of pathogen- or danger-
associated molecular patterns. Pro-interleukin 1β (pro-IL-1β) accumulates after a primary
inflammatory signal, and this accrual is frequently the result of activation of NF-κB. This
first signal, which often relies on the activation of NF-κB, can also modulate NLR
expression7.
Although most inflammasome NLR proteins do not alter NF-κB signaling, a small number
of NLR proteins can positively modulate NF-κB activity after specific stimuli. For example,
the receptors Nod1 and Nod2 are associated with activation of NF-κB after stimulation with
peptidoglycan8–11. Both Nod1 and Nod2 associate with the adaptor RIP2, which can lead to
its Lys63 (K63)-linked ubiquitination by the E3 ubiquitin ligases cIAP1 and cIAP2 and
enhancement of the activation of NF-κB12–15. Although Nod1 and Nod2 are associated with
the activation of NF-κB, NLR proteins are also able to attenuate inflammatory pathways.
NLRP12 inhibits the canonical NF-κB signaling pathway by preventing the accumulation of
hyperphosphorylated kinase IRAK1 and noncanonical signaling via NF-κB through
association with and degradation of NIK, a kinase necessary for phosphorylation of the
serine-threonine kinase IKKα and downstream processing of the NF-κB precursor p100 to
the p52 NF-κB subunit16. Nlrp12-null mice have more activation of canonical and
noncanonical NF-κB in models of colitis and colon cancer17,18. NLRX1 and NLRC5 have
been described as having inhibitory effects on proinflammatory signaling. NLRX1 can
inhibit the type I interferon pathway by interfering with the adaptor MAVS–RNA helicase
RIG-I pathway and the NF-κB pathway via the signaling adaptor TRAF6 (refs. 19–21), and
NLRC5 inhibits type I interferon and NF-κB22,23. However, there is controversy about the
role of NLRC5 as an activator or inhibitor of those pathways both in cell lines and in
Nlrc5−/− mice24–26.
Activation of NF-κB is a key regulator of inflammation and can be promoted through
various stimuli, which results in the production of a plethora of proinflammatory cytokines,
including tumor-necrosis factor (TNF), IL-1β and IL-6. NF-κB can be stimulated through
the receptor for IL-1 or Toll-like receptors (TLRs) to activate the IKK complex, which leads
to the translocation of heterodimers of the NF-κB subunits p65 and p50 to the nucleus27–30.
Myd88 and TRIF are adaptors required for the recruitment of IRAK1, IRAK4 and TRAF6,
which leads to activation of the kinases TAK1 and IKK. Protein modifications such as
ubiquitination of IRAK1 and TRAF6 (refs. 31, 32) and phosphorylation of TAK1 and IKK33
are essential for this pathway34,35. TRAF proteins are key components of activation of the
immune system. During activation, TRAF molecules autoubiquitinate through the E3
ubiquitin ligase in their RING domain, except for TRAF1, which lacks a RING domain36.
K48-linked ubiquitin typically is associated with degradation via the 26S proteosome. K63-
linked ubiquitin is nondegradative. It can cause a conformational change, act as a scaffold or
change localization of the substrate and cause activation of TRAF6 (refs. 37, 38). Because
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ubiquitination of TRAF6 is a key regulatory event, it is often a target for regulation by
inhibitors of NF-κB, such as A20 and CYLD39–43.
NLRC3 (CLR16.2) is an understudied NLR, and its function has been examined in only one
study, to our knowledge, through the use of overexpression systems in cell lines in which
NF-κB activation was diminished in the presence of overexpressed NLRC3 (ref. 44). Here
we describe an inhibitory mechanism used by NLRC3 to regulate NF-κB through interaction
with TRAF6 and to alter the ubiquitination state of TRAF6. Studies of Nlrc3−/− mice
confirmed the inhibition of proinflammatory signaling, K63-linked ubiquitination of TRAF6
and nuclear translocation of NF-κB by NLRC3. NLRC3 therefore serves as a checkpoint to
prevent a dysregulated inflammatory response.
RESULTS
NLRC3 inhibits MyD88-dependent activation of NF-κB
NLRC3 is expressed mainly by cells of the immune response44, so to better understand its
function, we focused on the innate immune pathway, specifically TLR signaling pathways.
TLRs and MyD88 are important for the detection of bacterial and viral pathogen-associated
molecular patterns and are often the first molecules to respond to infection. To initially
assess the function of NLRC3, we transfected human embryonic kidney (HEK293T) cells
with an NF-κB luciferase reporter vector, an activating protein and increasing
concentrations of NLRC3. NLRC3 significantly inhibited NF-κB activation in a dose-
dependent manner in response to an activating signal from MyD88 and TRAF6 and, to a
lesser but not significant extent, through IRAK, but not through IKKα or p65 (Fig. 1a).
These results suggested that NLRC3 was able to interfere with upstream signaling via
MyD88 and/or TRAF6 but not downstream activation by IKKα or p65.
As myeloid-monocytic cells are the main cell types that engage in TLR signaling, we
assessed the ability of NLRC3 to inhibit MyD88-dependent activation of NF-κB in the
human monocyte-like THP-1 cell line. We transduced THP-1 cells with recombinant
retrovirus expressing a stable short hairpin RNA that targets mRNA encoding NLRC3
(shNLRC3) or overexpressing a vector encoding NLRC3. We found substantial expression
of NLRC3 in human monocytic cell lines (THP-1 and U937) and of Nlrc3 in mouse primary
bone marrow macrophages (Supplementary Fig. 1a). We confirmed by real-time PCR the
overexpression of NLRC3 and lower expression of mRNA encoding NLRC3 achieved
through the use of shNLRC3 (Supplementary Fig. 1b). To determine if NLRC3 was
involved in TLR signaling, we stimulated those THP-1 lines with lipopolysaccharide (LPS).
Overexpression of NLRC3 resulted in less TNF and IL6 mRNA, whereas shNLRC3 resulted
in more TNF and IL6 mRNA (Fig. 1b, c). In addition, the secretion of TNF and IL-6 was
also inversely associated with the expression of NLRC3 mRNA (Fig. 1d, e). These findings
suggested that NLRC3 may be a negative regulator of NF-κB signaling in monocytes.
The transcription of genes encoding cytokines occurs after MyD88-TRAF6 signaling,
followed by activation of the IKK complex and phosphorylation of the NF-κB inhibitor
IκBα. This post-translational modification leads to the ubiquitination and subsequent
degradation of IκBα. To assess if the differences observed in cytokine production were due
to changes in IκBα modification, we assessed total and phosphorylated IκBα by
immunoblot analysis. In cells overexpressing NLRC3, phosphorylation of IκBα was slightly
delayed (Fig. 1f). Conversely, cells with shNLRC3 had early phosphorylation of IκBα (Fig.
1f). Together these results indicated that NLRC3 diminished LPS-dependent NF-κB
signaling in a human monocytic cell line.
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NLRC3 inhibits NF-κB by association with TRAF6
TRAF molecules are important intermediaries of the activation of NF-κB. Overexpression
of NLRC3 was sufficient to inhibit the activation of NF-κB by TRAF6. To determine if
NLRC3 was able to interact with TRAF6, we transiently transfected HEK293T cells to
express V5-tagged TRAF6 (V5-TRAF6) and hemagglutinin-tagged NLRC3 (HA-NLRC3)
and coimmunoprecipitated proteins from the cells; we found that NLRC3 associated with
TRAF6 (Fig. 2a). Because of the nature of overexpression systems and the lack of a high-
quality antibody for the detection of endogenous NLRC3, we were unable to confirm that
this interaction occurred with physiological amounts of NLRC3 or TRAF6. However, a
search for TRAF-binding domains in NLRC3 showed that human NLRC3 has two major
TRAF2-binding motifs ((P/S/A/T)-X-(Q/E)-E, where ‘P/S/A/T’ indicates proline, serine,
alanine or threonine, ‘X’ indicates any amino acid, and ‘Q/E’ indicates glutamine or
glutamic acid) in its NBD (Fig. 2b). However, it has been noted that the TRAF2-binding
domain is not specific to TRAF2 but is indicative of a general TRAF-binding motif45. For
example, Nod2 has a predicted TRAF2-binding motif in its nucleotide-binding
oligomerization domain, which facilitates association with TRAF4 (ref. 46). We found that
the region in NLRC3 with the TRAF motif is conserved across various species (Fig. 2c).
Because of homology in the NLR family, we searched the sequences of other NLR proteins
for TRAF-binding motifs. We found that most NLR proteins have a major TRAF2-binding
sequence, a minor TRAF2-binding motif and/or a TRAF6-binding motif, as described
before47 (Table 1). These data indicated that interactions between NLR and TRAF
molecules may be prevalent and identified previously unknown potential intersections of
NLR proteins with TRAF proteins.
We next assessed the possibility that NLRC3 associates with TRAF6 through that TRAF-
binding motif in the NBD. We substituted alanine for all four amino acids in either the
TRAF-binding site with the sequence Ser-Leu-Gln-Glu (site 1) or the TRAF-binding site
with the sequence Ser-Val-Glu-Glu (site 2). We expressed those NLRC3 mutants together
with V5-TRAF6 in HEK293T cells and assessed the association of TRAF6 and NLRC3 by
immunoprecipitation of V5-TRAF6 and immunoblot analysis of HA-NLRC3. The
substitution in site 1 of NLRC3 resulted in much less association, whereas the substitution in
site 2 had less or little effect (Fig. 2d). These findings indicated that the first TRAF-binding
motif in the NBD of NLRC3 was important for its association with TRAF6.
NLRC3 influences the degradation and ubiquitination of TRAF6
We next explored the mechanism by which NLRC3 affected the function of TRAF6. When
we transiently transfected HEK293T cells to express V5-TRAF6 and/or HA-NLRC3, we
consistently noted less V5-TRAF6 in the presence of HA-NLRC3, whereas the amount of
TRAF2 or TRAF3 (control proteins) remained unchanged (Fig. 3a). Additionally, the
NLRC3-dependent decrease in TRAF6 protein was dose dependent (Fig. 3b). Proteins are
frequently targeted to the proteosome for degradation by conjugation with K48-linked
ubiquitin chains, whereas K63-linked ubiquitin is a common activating signal. Other NLR
proteins that regulate NF-κB, such as Nod1 and Nod2, do so through interactions with
ubiquitinated substrates, such as RIP2 (refs. 13, 14). To determine if NLRC3 affected the
ubiquitination of TRAF molecules, we transfected HEK293T cells to express Myc-tagged
TRAF2 or TRAF6, as well as hemagglutinin-tagged ubiquitin, in the presence or absence of
vector encoding Flag-tagged NLRC3. We lysed cells in a stringent 1% SDS buffer and
boiled them so that only covalent modifications remained. We immunoprecipitated TRAF
proteins and quantified ubiquitin by densitometry. The presence of NLRC3 did not
significantly affect the amount of ubiquitin on TRAF2 (Fig. 3c, d) but did result in less
ubiquitination of TRAF6 (Fig. 3c, d). To determine the type of ubiquitin on TRAF6 that was
affected by NLRC3, we transfected HEK293T cells to express TRAF6 with NLRC3 in the
Schneider et al. Page 4













presence of plasmid encoding total ubiquitin, K48-linked ubiquitin or K63-linked ubiquitin.
The presence of NLRC3 resulted in less total ubiquitin on TRAF6, accompanied by less
K63-linked ubiquitin, but there was no significant change in K48-linked ubiquitin (Fig. 3e,
f). Although there was an apparent trend by which the presence of NLRC3 resulted in more
K48-linked ubiquitination of TRAF6, the difference was variable and was not significant.
This indicated that NLRC3 diminished the activating K63-linked ubiquitination of TRAF6
but left unchanged or enhanced the degradative K48-linked ubiquitination. The finding that
K48-linked ubiquitin on TRAF6 remained in the presence of NLRC3 was consistent with
the overall lower abundance of TRAF6 in the presence of NLRC3. Additionally, if NLRC3
prevented the accumulation of K63-linked ubiquitin on TRAF6 and left only K48-linked
ubiquitin, then TRAF6 may have not only remained inactive but also may have been
increasingly targeted to the proteosome. Because tight regulation of TRAF6 is important for
NF-κB signaling, NLRC3 may inhibit proinflammatory signaling through this modification.
More proinflammatory cytokines made by Nlrc3−/− macrophages
The studies reported above relied on overexpressed proteins, which are useful for
determining mechanistic events but can provide results that are inconsistent with
endogenous processes. Therefore, to address the physiological role of NLRC3 in vivo, we
generated Nlrc3-deficient (Nlrc3−/−) mice by homologous recombination (Fig. 4a). The
NBD, which is encoded by exon 3, is important for NLR protein function; therefore, we
designed a targeting vector that, after homologous recombination with the endogenous
locus, removed exon 3, replacing it with the gene encoding resistance to the aminoglycoside
antibiotic geneticin. We used embryonic stem cells from 129S6 mice that expressed the
properly modified locus to generate chimeric mice. We bred male chimeras with female
C57BL/6 mice and identified germline transmission in the offspring by coat color and
confirmed this by Southern blot analysis (Fig. 4b). We bred those offspring to C57BL/6J
mice. We intercrossed heterozygous (Nlrc3+/−) mice for nine generations to generate the F9
Nlrc3−/− mice used in these studies. Mendelian ratios for each genotype and the distribution
of the targeted allele among male and female mice were normal. We verified genotype by
PCR and determined absence of expression by RT-PCR (Supplementary Fig. 2a). Nlrc3−/−
mice did not seem to have any anatomic abnormalities, similar to mice lacking other NLR
proteins. Reproductive performance, gender distribution, frequency of lymphocytes and
monocytes in the spleen, and total number of splenocytes, peritoneal cells and bone marrow
cells were equivalent to those of wild-type mice (Supplementary Fig. 2b–e).
As NLRC3 resulted in less production of proinflammatory cytokines in human cell lines
(Fig. 1), we sought to assess if a change in cytokines also occurred in Nlrc3−/− macrophages
treated with LPS and whether this change was due to a greater abundance of transcripts
encoding proinflammatory cytokines. The cytokine-encoding genes Tnf, Il1b, Il6 and Il12
are targets for activation by NF-κB, and expression of these genes increases considerably
after stimulation of the TLR. To determine if Nlrc3−/− macrophages had higher expression
of genes encoding proinflammatory cytokines, we measured transcripts by real-time PCR.
There was much higher expression of those cytokine-encoding genes in Nlrc3−/− peritoneal
macrophages than in wild-type cells after 1 h of stimulation with LPS (Fig. 4c). However,
there was no difference between wild-type and Nlrc3−/− cells in expression of the gene
encoding interferon-β after stimulation with LPS (Fig. 4d). At later time points, the
expression of Tnf, Il1b and Il6 in Nlrc3−/− cells was similar to that in wildtype cells.
Differences in the expression of TLR or TLR-signaling molecules could lead to variation in
cytokine release. However, the expression of Tlr4 and Traf6 in peritoneal macrophages was
similar in wild-type and Nlrc3−/− cells (Fig. 4e). Additionally, a negative feedback loop can
be activated through NF-κB, by which expression of NF-κB inhibitors such as A20, CYLD
and IκBα is increased. To assess this possible repressive effect, we measured expression of
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the genes encoding A20 (Tnfaip3; called ‘A20’ here), CYLD (Cyld) and IκBα (Nfkbia)
before and after stimulation with LPS. We observed no difference between wild-type and
Nlrc3−/− macrophages in their expression of Cyld or Nfkbia before or after stimulation (Fig.
4f). In contrast, A20 expression was modestly higher in Nlrc3−/− macrophages than in wild-
type macrophages at 1 h after stimulation with LPS and was much higher in Nlrc3−/−
macrophages than in wild-type macrophages by 6 h after treatment with LPS (Fig. 4f). That
finding was in agreement with published reports indicating a negative regulatory loop
between activation of NF-κB and A20 expression48. These data indicated that the absence of
NLRC3 resulted in an early increase in the transcription of NF-κB-dependent genes
activated by TLR4. That change was not preceded by a change in the expression of Tlr4,
Traf6, Cyld or Nfkbia (Fig. 4d–f).
Peritoneal macrophages from Nlrc3−/− mice also secreted more TNF and IL-6 than did wild-
type macrophages in response to TLR agonists that activate signaling via the MyD88-
dependent pathway (the synthetic lipopeptide Pam3Cys for TLR2; LPS for TLR4; and
single-stranded RNA for TLR7 and TLR8) but not to a significant extent in response to an
agonist that activates signaling via the TRIF-dependent pathway (the synthetic RNA duplex
poly(I:C) for TLR3; Fig. 5a). Additionally, quantification of TRAF6 protein in wild-type
and Nlrc3−/− peritoneal macrophages showed that cells lacking NLRC3 had more TRAF6
(Fig. 5b). Bone marrow–derived macrophages also had more TRAF6, although this greater
abundance was not as substantial and varied by experiment (data not shown). That
observation supported the earlier finding obtained with HEK293T cells showing that
overexpression of NLRC3 led to less TRAF6 protein. To determine if Nlrc3 expression was
affected by stimulation of the TLR, we measured Nlrc3 expression in macrophages after in
vitro stimulation with LPS. Expression diminished soon after stimulation and remained low
throughout the assay interval, although by the end of the study, there was a modest recovery
(Fig. 5c). As the macrophage culture began to lose viability at those later time points, the
lack of recovery of Nlrc3 expression might have been to due to the unhealthy state of the
culture. To overcome the artifacts of tissue culture, we examined the in vivo effect of LPS
on Nlrc3 expression in peritoneal cells isolated at various time points after intraperitoneal
injection of LPS. Nlrc3 expression decreased after stimulation and this decrease was
sustained for 48 h, but by 108 h, Nlrc3 expression recovered to the amount before
stimulation (Fig. 5d). That finding suggested that the decrease in Nlrc3 expression during
LPS treatment was probably necessary for the inflammatory response to proceed, whereas
its recovery later restored the basal resting state (Fig. 5d). Thus, regulation of Nlrc3 mRNA
expression provides a mechanism by which NLRC3 function is controlled.
Because there was less TRAF6 protein in the presence of NLRC3, whereas LPS diminished
Nlrc3 expression, we assessed the effect of NLRC3 on TRAF6 during stimulation with LPS.
We measured TRAF6 protein in wild-type and Nlrc3−/− peritoneal macrophages before and
after stimulation with LPS. In basal conditions, Nlrc3−/− macrophages had much more
TRAF6 than did wild-type cells. However, at 24 h after LPS stimulation, when Nlrc3
expression was low in wild-type cells, wild-type and Nlrc3−/− cells had an equal amount of
TRAF6 (Fig. 5e).
More activation of TRAF6 and NF-κB in Nlrc3−/− macrophages
To better determine the function of NLRC3 in NF-κB signaling, we explored the mechanism
by which NLRC3 inhibited the macrophage proinflammatory response. Because we had
observed less ubiquitinated TRAF6 in the presence of NLRC3 when those proteins were
overexpressed, we assessed if the deletion of Nlrc3 resulted in more ubiquitination of
TRAF6. To measure ubiquitination, we activated TRAF6 by timed stimulation of bone
marrow–derived macrophages with LPS. We immunoprecipitated endogenous TRAF6 and
measured K63-linked ubiquitin associated with TRAF6 through the use of an antibody
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specific for K63-linked ubiquitin chains. We did not study K48-linked ubiquitin because
antibodies to K48-linked ubiquitin did not work properly in our experiments. We used
stringent lysis conditions to disrupt any noncovalent bonds. There was more K63-linked
ubiquitin on TRAF6 from Nlrc3−/− cells than on TRAF6 from wild-type control cells at all
time points, and possibly even in the absence of stimulation (Fig. 6a). These data suggested
that NLRC3 negatively regulated K63-linked ubiquitination of TRAF6, which would be
expected to diminish downstream signaling. To determine if the absence of NLRC3 led to
more NF-κB signaling, we assessed the nuclear localization of p65 and the abundance of
p65 and IκBα. After stimulation with LPS, the nuclei of Nlrc3−/− macrophages had much
more p65 than did those of wild-type cells (Fig. 6b); nearly 70% more nuclei contained p65
in Nlrc3−/− macrophages than in wild-type cells (Fig. 6b). Additionally, there was earlier
and more-prolonged phosphorylation of p65 in Nlrc3−/− macrophages than in wild-type cells
(Fig. 6c). That greater phosphorylation correlated with more-rapid loss of total IκBα and
lack of recovery of IκBα at 60 min (Fig. 6d). TRAF6 can affect other proinflammatory
pathways, notably the mitogen-activated protein kinase signaling pathway. To determine if
the effect of NLRC3 on TRAF6 was specific for the activation of NF-κB, we examined
phosphorylation of the mitogen-activated protein kinases p38, Erk and Jnk after stimulation
with LPS. Signaling via this pathway was not affected much in the absence of NLRC3 (Fig.
6e).
Enhanced response of Nlrc3−/− mice to endotoxic shock
The experiments reported above indicated that NLRC3 functioned as an attenuator of the
response to LPS in macrophages. We next assessed its role as an in vivo regulator of the
severe inflammatory condition of endotoxic shock. LPS is a common component of Gram-
negative bacteria and induces the production of proinflammatory cytokines. An uncontrolled
immune response to LPS can lead to a cytokine storm and serves as a surrogate model of
sepsis. The NF-κB pathway is a chief driver of this inflammation. Because of the enhanced
release of proinflammatory cytokines in response to TLR agonists in both human and mouse
cells lacking NLRC3, we hypothesized that Nlrc3−/− mice would be more susceptible to
LPS-induced shock. To assess this, we injected wild-type and Nlrc3−/− mice with LPS or
PBS (vehicle control) and monitored temperature and weight. In response to a nonlethal
dose of LPS, wild-type and Nlrc3−/− mice initially had a similar drop in temperature and
weight. However, Nlrc3−/− mice had a significant delay in recovery, as measured by their
lower body temperature and weight after challenge with LPS (Fig. 7a, b).
The body temperatures of wild-type and Nlrc3−/− mice began to diverge 18–42 h after LPS
challenge, with Nlrc3−/− mice showing a greater drop than that of control mice. Similarly,
Nlrc3−/− mice lost more weight than control mice did from 42 h to 88 h after LPS
stimulation. To determine a possible cause for the diminished health of Nlrc3−/− mice, we
killed the mice at 24 h after the LPS challenge. Because we injected the mice
intraperitoneally, we collected peritoneal lavage fluid to assess not only cellularity due to
inflammatory infiltrates but also local cytokine concentrations, and we collected serum to
assess systemic cytokine concentrations. The serum of Nlrc3−/− mice had a significantly
higher concentration of IL-6 at 24 h after LPS treatment than did wild-type serum;
additionally, the concentration of TNF was also higher in Nlrc3−/− serum than in wild-type
serum (Fig. 7c). We noted a much greater abundance of Il6 transcripts and IL-6 protein in
the peritoneal cavity of Nlrc3−/− mice than in that of wild-type mice at 24 h after LPS
challenge (Fig. 7d, e). By 48 h, the concentration of IL-6 was lower in both wild-type and
Nlrc3−/− mice (Fig. 7c, d). Additionally, Nlrc3−/− peritoneal cells had higher expression of
genes encoding the proinflammatory cytokines IL-6 and TNF than did wild-type peritoneal
cells (Fig. 7e). The absence of NLRC3 affected TNF less than it affected IL-6 and did not
have a significant effect on IL-1β (Fig. 7c–e). As Nlrc3−/− peritoneal macrophages produced
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more proinflammatory cytokines ex vivo, it is possible that the enhancement in systemic
cytokines was due to changes in cellular composition. To assess this, we examined the
cellular composition of the peritoneal cavity of wild-type and Nlrc3−/− mice after challenge
with LPS. Although there was not a significant difference between the mice in the total
proportion of cells in the peritoneal cavity, there was slightly greater frequency of peritoneal
monocytes in Nlrc3−/− mice than in wild-type mice (Fig. 7f). However, this modest
difference was probably not responsible for greater differences in the abundance of Il6
transcripts and IL-6 protein. Together these results indicated that NLRC3 had a protective
role in endotoxic shock by diminishing proinflammatory cytokines, especially IL-6 and, to a
lesser extent, TNF. In contrast to inflammasome NLR proteins, NLRC3 had little effect on
IL-1β. The lack of an effect on IL-1β might have accounted for the relatively modest effect
of NLRC3 on body temperature during exposure to endotoxins.
DISCUSSION
Although it has long been accepted that Nod1 and Nod2 are important for the activation of
NF-κB, NLR proteins that negatively affect this pathway and regulate inflammatory
responses have not been widely documented because of the lack of in vivo evidence16. In
many cases, a complete mechanism has not been fully described and the inhibitory effect on
NF-κB is partial20,21,23,24. Our study here has provided evidence that NLRC3 negatively
affected the activation of NF-κB and has suggested that multiple NLR proteins may serve as
regulatory checkpoints for inflammation. So far, physiological roles for inhibitory NLR
proteins have been described for NLRX1 and NLRP12, whereby NLRX1 interacts with
TRAF6 and diminishes its function in transformed cells, and NLRP12 promotes the
degradation of NIK possibly through interactions with TRAF3 (refs. 17, 20, 21). However,
the mechanism by which NLRX1 affects TRAF6 function and how NLRP12 affects TRAF3
remain elusive. It will be useful to understand the mechanisms that govern these interactions
because the ability to target one molecule without disrupting all processes is ideal for the
development of disease-directed therapy.
Our study has provided in vivo evidence that NLRC3 functioned as an attenuating
checkpoint for the production of inflammatory cytokines in macrophages. NLRC3
diminished the production of inflammatory cytokines in vivo and improved health in an
endotoxic shock model. Furthermore, our study has provided a mechanism whereby NLRC3
negatively affected endotoxin signaling by associating with TRAF6, which led to several
effects on TRAF6. These effects include a lower abundance of TRAF6 protein and less
activation of TRAF6 by K63-linked ubiquitination, followed by less activation and nuclear
translocation NF-κB. Our results have suggested a negative feedback loop whereby TLR
signaling resulted in lower expression of NLRC3, which thus ‘released’ the checkpoint and
permitted activation of NF-κB to proceed. Control of NF-κB through a decrease in the
ubiquitination of TRAF6 is a critical step in ensuring TLR responses are not dysregulated
and involves other checkpoint molecules, including A20 and CYLD49. Our work has
described a regulatory function for NLRC3 and has emphasized the need for multiple and
precise tunings of TRAF6 signaling.
The bioinformatics data presented here have identified many putative interaction sites
between NLR proteins and TRAF proteins. Published studies have confirmed some of these
interactions and have demonstrated that they are functionally revelant20,21,46. A diverse set
of signaling pathways is mediated by the TRAF molecules, including those that control
proliferation, survival and inflammation. Given the range of functions of the NLR proteins
that have been characterized and the number of NLR proteins that are yet to be
mechanistically defined, we speculate that the functional and biochemical interactions of
NLR proteins and TRAF proteins may compose an intricate checks-and-balances system of
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control, and we propose that these complexes be called ‘TRAFasomes’. In addition, our
study has shown that TLR signaling resulted in lower expression of NLRC3, which reflected
a feedback loop between NLR proteins and TLRs.
As a working model, we hypothesize that under resting conditions, NLRC3 associated with
TRAF6 and prevented activation by inhibiting the ability of TRAF6 to autoubiquitinate.
After stimulation, repression by NLRC3 was released and proinflammatory signaling was
promoted partly through lower expression of the gene encoding NLRC3. In the absence of
NLRC3, inflammation was accelerated, which indicated that NLRC3 represents a
checkpoint for TLR-induced inflammation. Expression of the gene encoding NLRC3 was
lowered by LPS, but then it began to recover slowly after the inflammatory response
subsided. This supported the hypothesis that NLRC3 prevents basal signaling rather than
acting as an inducible inhibitor. In sum, our report has identified an NLR protein that
affected TRAF6 ubiquitination as a mechanism for altering TLR signaling, whereas TLR
signaling lowered Nlrc3 expression to allow activation of the immune system.
ONLINE METHODS
Cell culture, transfection, coimmunoprecipitation and immunoblot analysis
HEK293T cells and peritoneal macrophages were grown in DMEM supplemented with 10%
FBS and penicillin-streptomycin. Resident peritoneal macrophages were removed by lavage
and cultured overnight and nonadherent cells were removed, followed by replacement with
fresh medium. Bone marrow-derived macrophages were cultured for 6 d in DMEM
supplemented with 10% FBS, L-glutamine, penicillin-streptomycin and 20% conditioned
medium from L929 mouse fibroblasts. Transfections were done with FuGENE6 according to
the manufacturer’s protocol (Roche). Plasmids encoding the following were used: Myc-
tagged TRAF6, V5-TRAF6, HA-NLRC3 (ref. 45), NF-κB-luciferase reporter and p65.
NLRC3 site mutants were made by standard molecular biology subcloning techniques.
Hemagglutinin-tagged MyD88 and Flag-tagged IRAK were provided by S. Ghosh; plasmids
encoding hemagglutinin-tagged K48-linked ubiquitin and K63-linked ubiquitin were
obtained from Y. Xiong; and Flag-tagged IKKα was obtained from A. Baldwin. Cells were
lysed in 1% Triton X-100 isotonic buffer and coimmunoprecipitation was done with V5-
agarose beads (Sigma) or 1 μg anti-TRAF6 (D-10; Santa Cruz) and UltraLink Protein A/G
beads (Pierce). Immunoblots were probed with antibody to Flag-tagged horseradish
peroxidase (M2; Sigma), antibody to V5-tagged horseradish peroxidase (R961-25;
Invitrogen), anti-TRAF6 (D-10 or H-274; Santa Cruz), antibody to phosphorylated IκBα
(2859S; Cell Signaling Technology), anti-IκBα (4812; Cell Signaling Technology),
antibody to K63-linked ubiquitin (BML-PW0600; Enzo Lifesciences), anti-actin-horseradish
peroxidase (C-1 1; Santa Cruz).
Stable overexpressing and knockdown THP-1 lines
Short hairpin RNA cassettes were made with a small interfering expression cassette kit from
Ambion (5′-
CGGCGAAGCTTTTTCCAAAAAAGGGAACACGACTTCCACACATCTCTTGAATGT
GTGAAGTCGTGTTCCCCGGTGTTTCGTCCTTTCCACAAG-3′). These constructs were
subcloned into the pHSPG vector via EcoRV and XbaI. The pHSPG–Flag-tagged NLRC3
plasmid was created by PCR amplification of sequence encoding NLRC3 with an amino-
terminal Flag tag and subcloning into pHSPG via 5′ XhoI-3′ XhoI. Recombinant
retroviruses were created by transient transfection of human A293T human embryonic
kidney cells and THP-1 cells were transduced with virus as described50. Cells were sorted
for expression of green fluorescent protein and were cultured in supplemented RPMI-1640
medium with 10% FBS.
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HEK293T cells were transfected as described above with 150 ng NF-κB-luciferase; 0, 100
or 250 ng NLRC3; 0, 150 or 250 ng pcDNA3.1 (empty vector); and 250 ng vector encoding
MyD88, IRAK, TRAF6, IKKα or p65. Then, 24 h after transfection, cells were lysed in
Reporter Assay Buffer (Roche). Plates were ‘read’ on a luminometer with the addition of
ATP buffer (100 μM ATP, glycine-glycine, MgSO4, KHPO4, EGTA and DTT) and
luciferin buffer.
Ubiquitination assay
For in vitro ubiquitination assays, HEK293T cells were transfected and then lysed 24 h later
in 1% SDS isotonic buffer. Lysates were boiled for 15 min for removal of any noncovalent
interactions, then were centrifuged for 10 min at 16,000 r.p.m., then supernatants were
transferred to a new tube. Lysates were diluted with 1% Triton X-100 buffer and substrate
molecules were immunoprecipitated with Myc or V5 agarose gel (Sigma).
Real-time PCR
RNA was extracted from THP-1 cells or peritoneal macrophages with the RNeasy Mini Kit
according to the manufacturer’s protocol (Qiagen). The cDNA was synthesized with total
RNA, Superscript III (Invitrogen) and RNase inhibitors (Roche) according to the
manufacturer’s protocol (Invitrogen). The expression of human and mouse genes encoding
TNF, IL-6, IL-1b, TNF, IL-12, TLR4, A20, CYLD, interferon-β, IκBα, TRAF6 and
GAPDH was assessed by real-time PCR with mouse Taqman Gene Expression Assays
(Applied Biosystems); results were normalized to expression of the gene encoding GAPDH
and were quantified by the change-in-threshold method (ΔΔCT).
Confocal microscopy
Macrophages (4 × 105) were seeded onto coverslips in 24-well dishes and were grown for
24 h before stimulation with 1 μg/ml LPS. Cells were fixed with 4% paraformaldehyde,
followed by ice-cold methanol. Cells were stained with anti-p65 (D14E12; Cell Signaling)
and Alexa Fluor 546-conjugated antibody to rabbit (A-11035; Invitrogen) and then were
counterstained for nucleic acids with Hoechst 33342. Cells were analyzed with a Zeiss LSM
710 laser-scanning confocal microscope.
Enzyme-linked immunosorbent assay
Peritoneal lavage fluid, serum and cell culture supernatants were collected and assayed for
cytokines. Cytokine production was measured by enzyme-linked immunosorbent assay of
human (eBioscience) or mouse (BD Bioscience) TNF, IL-1β and IL-6 according to the
manufacturer’s protocol.
Generation of Nlrc3−/− mice and in vivo LPS treatment
The 3′ arm of homology of the Nlrc3-deficient construct was obtained by PCR (Takara LA
Taq) through the use of mouse 129/Sv genomic DNA with a forward primer for exon 4 (E4f;
5′-CCTGTGATGGAGTTGCTGGGCAGCGTGCTGAGTGG-3′) and a reverse primer for
exon 6 (E6r; 5′-AGCCCCCGGTGGTCCAATGCTGTT ACTCCGGAGG-3′). The
resulting product was cloned into pCR2.1-TOPO (Invitrogen). The entire fragment spanning
3,539 base pairs was excised with the restriction enzyme PvuII (New England Biolabs) and
ligated into the PmeI site of the targeting vector pOS (R. Thresher) with the Rapid DNA
Ligation Kit (Roche). The 5′arm of homology was obtained by PCR with intron 1 forward
primer 1 (I1f) (5′-AGAGCACTTGCTGTTCATGCTGAGGTCGCACGACTTG) and exon
2 reverse primer (E2r) (5′-TTCACCTGCTCAGCTGGGGAGCCAACACTGT-3′). The
PCR product was cloned into pCR2.1-TOPO. A 1,902–base pair XbaI intron 1–exon 2
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fragment was subcloned into the NheI site in pOS. Both arms of homology were sequenced
in their entirety for confirmation of the structure of the targeting construct. The targeting
construct was transfected by electroporation into 129S6/Sv embryonic stem cells and cells
were maintained for 14 under selection with the aminoglycoside G418 and gancyclovir. A
clone identified as positive by Southern blot analysis and PCR was injected into C57BL/6
blastocysts. Chimeric male mice were crossed to either 129SV6 female mice or with
C57BL/6 female mice. The resulting pups were screened by PCR for the presence of the
mutated locus. DNA obtained from mouse tails was digested with XbaI, resolved by
electrophoresis through a 0.8% TBE gel and transferred overnight to Zetaprobe nylon
membranes (Bio-Rad). A 672–base pair probe of sequence upstream of exon 1was generated
by PCR with forward primer 5′-TGCTCAGTCCCAGAATGGAGATCC-3′ and reverse
primer 5′-GCATCCTGCTCCGCCCATGCCATC-3′, then was cloned into pCR2.1-TOPO
(Invitrogen), excised with EcoRI, gel-purified and labeled with the Prime-a-Gene labeling
system (Promega). The resulting fragments of 14.3 kilobases and 13.1 kilobases
(representing the wild-type and targeted allele, respectively) were detected by Southern blot
analysis of mouse genomic DNA digested with HindIII. Primers outside the region of
homologous recombination were used for confirmation of the correct integration of the
targeted allele (If1 (5′-AGCACTTGCTGTTCATGCTGAGGTCGCACGACTTG-3′) and
NeoPro, and E10r (5′-CATGTCACTGATGGAATTGC-3′) and Neo3′-2 (5′-
TTCTATCGCCTTCTTGACGAG-3′)). Multiplex PCR was used for genotyping with
primers specific for the 5′ arm of homology (Common (5′-
ATTCACAACTTCTGGCTGCAAACAC-3′), NeoPro (5′-
GGCCACACGCGTCACCTTAATATGCG-3′) and wild-type reverse (5′-
CTCAGAGTGCTTCGGTATCCTTGAC-3′)). Heterozygous F1 progeny were interbred to
obtain Nlrc3−/− mice and were backcrossed for nine generations onto the C57BL/6
background. Mice were housed in a pathogen-free facility and maintained according to
Institutional Animal Care and Use Committee guidelines. For LPS challenge, 4.5 mg LPS
per kg body weight was administered intra-peritoneally. The temperatures and weights of
the mice were monitored three times a day for 10 d. For time-point studies, mice were killed
and serum and peritoneal lavage were collected. For all experiments, wild-type and Nlrc3−/−
mice were matched for age and sex. All peritoneal macrophages used were not preactivated
with thioglycollate.
Statistics
Significance was determined with Student’s t-test or one-way analysis of variance with
Tukey’s or Newman Kuhls post-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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NLRC3 inhibits MyD88- and TRAF6-dependent activation of NF-κB. (a) Luciferase
activity in HEK293T cells transfected with a luciferase reporter vector driven by an NF-κB-
responsive promoter, plus empty vector (EV) or vector encoding MyD88, IRAK, TRAF6,
IKKα or p65, and increasing concentrations (wedges) of a vector encoding NLRC3; results
are presented relative to results obtained in the absence of NLRC3. *P < 0.001 and **P <
0.0001 (Student’s t-test). (b, c) Expression of TNF and IL6 in THP-1 cell lines stably
transduced with retrovirus expressing empty vector or Flag-tagged NLRC3 (b) or empty
vector or shNLRC3 (c) and stimulated with LPS; results were normalized to the expression
of ACTB (encoding β-actin) and are presented relative to those of untreated cells. (d, e)
Production of TNF and IL-6 by THP-1 cells transduced as in b(d) or c(e) and simulated with
LPS. (f) Immunoblot analysis of total and phosphorylated (p-) IκBα in THP-1 cells
transduced as in b, c and simulated with LPS; actin serves as a loading control throughout.
Data are representative of at least three independent experiments (mean and s.e.m. in a–e).
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NLRC3 inhibits NF-κB by association with TRAF6.
(a) Immunoprecipitation (IP) of V5-TRAF6 (with anti-V5 agarose) from HEK293T cells
transiently transfected to express HA-NLRC3 plus V5-TRAF6 (+) or empty vector (−),
followed by immunoblot analysis (IB) with antibody to hemagglutinin (anti-HA) or anti-V5.
(b) Major TRAF2-binding motifs (bold) in the NBD of NLRC3, identified by a
bioinformatics search. Numbers above diagram and before sequences indicate amino acid
positions. Hs-, Homo sapiens; CARD, caspase-recruitment domain; LRR, leucine-rich
repeat; Walker A and Walker B, ATP-binding motifs. (c) Conservation across species of
TRAF2-binding sites 1 and 2 from b. (d) Immunoprecipitation of V5-TRAF6 from
HEK293T cells transfected to express various combinations (below lanes) of V5-TRAF6
and hemagglutinin-tagged wild-type NLRC3 (HA-NLRC3) or NLRC3 mutants with
replacement of amino acids in TRAF2-binding site 1 (HA-site1AAAA) or site 2 (HA-
site2AAAA) with alanine, followed by immunoblot analysis with anti-hemagglutinin or
anti-V5. Data are representative of at least three independent experiments.
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NLRC3 promotes degradation of TRAF6 and prevents autoubiquitination of TRAF6. (a)
Immunoblot analysis of HEK293T cells transfected to overexpress vectors encoding Myc-
tagged TRAF2 or V5-tagged TRAF3 or TRAF6 with or without Flag- or HA-tagged
NLRC3. (b) Immunoblot analysis of HEK293T cells transfected with vector encoding V5-
TRAF6 (2 μg) and empty vector or increasing amounts (above lanes) of vector encoding
HA-NLRC3. (c) Immunoblot analysis of the ubiquitination of TRAF6 and TRAF2 in
HEK293T cells transfected to express Myc-tagged TRAF2 or TRAF6 and hemagglutinin-
tagged ubiquitin (HA-Ub) in the presence (+) or absence (−) of vector encoding Flag-tagged
NLRC3, assessed after (top) or without (below) immunoprecipitation with anti-Myc
agarose. (d) Densitometry of the bands c, showing the ubiquitination of TRAF2 (left) and
TRAF6 (right), presented relative to results obtained with cells transfected to express empty
vector (instead of Flag-tagged NLRC3), set as 100%. *P = 0.006 (Student’s t-test). (e)
Immunoblot analysis of K48-linked and K63-linked ubiquitination of TRAF6 in cells
transfected to express V5-TRAF6 with or without Flag-tagged NLRC3, plus plasmid
encoding hemagglutinin-tagged total ubiquitin (HA-Ub), K48-linked ubiquitin (HA-K48-
Ub) or K63-linked ubiquitin (HA-K63-Ub). (f) Densitometry of the bands e, showing the
total (left), K48-linked (middle) and K63-linked (right) ubiquitination of TRAF6,
normalized to total TRAF6 protein and presented as in d. *P = 0.025 and **P = 0.005
(Student’s t-test). Data are representative of at least three experiments (a, b) or are from six
(c, d) or five (e, f) independent experiments (average and s.e.m. in d and f).
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Nlrc3−/− macrophages produce more proinflammatory cytokines in response to TLR
agonists. (a) Strategy used to disrupt the Nlrc3 locus: homologous recombination of the
targeting construct (middle) with endogenous wild-type (WT) Nlrc3 (top) resulted in the
replacement of genomic sequence spanning and including the final 103 base pairs of exon 2
through the first 35 base pairs of exon 4 with the gene encoding the selectable marker for
geneticin (and neomycin) resistance (neo). Labels at top indicate primers: I 1f, intron 1
forward; E2r, exon 2 reverse; E4f, exon 4 forward; E6r, exon 6 reverse; E10r, exon 10
reverse. Below left (5′ probe), probe used in b that detects HindIII fragments (below
diagram) generated from the wild-type locus and the targeted (Mutant) locus (size, in
kilobases (kb), in parentheses). PGK-TK, gene encoding thymidine kinase linked to the
promoter of the gene encoding phosphoglycerate kinase; NeoPro, neo reverse primer;
Neo3′-2, neo forward primer (neo primers used to detect correct insertion of gene). (b)
Southern blot analysis of DNA obtained from tail biopsies of mouse pups generated by the
intercross of Nlrc3+/− mice (probe in a). (c) Expression of Tnf, Il6, Il1b and Il12 mRNA in
wild-type and Nlrc3−/− peritoneal macrophages stimulated with LPS, normalized to Gapdh
(encoding glyceraldehyde phosphate dehydrogenase) and presented relative to that in
untreated wild-type cells, set as 1. (d) Expression of the gene encoding interferon-β (Ifnb) in
wild-type and Nlrc3−/− peritoneal macrophages stimulated with LPS (presented as in c). (e)
Expression of Tlr4 and Traf6 in wild-type and Nlrc3−/− peritoneal macrophages stimulated
with LPS (presented as in c). (f) Expression of Cyld, A20 and Nfkbia in wild-type and
Nlrc3−/− macrophages stimulated with LPS (presented as in c). *P< 0.001 and **P< 0.0001
(one-way analysis of variance with Tukey’s post-test). Data are representative of one
experiment (b) or three independent experiments (c–f; error bars, s.e.m.).
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Nlrc3−/− macrophages produce more proinflammatory cytokines and TRAF6 in response to
LPS. (a) Production of TNF and IL-6 by wild-type and Nlrc3−/− peritoneal macrophages left
untreated (UT) or stimulated via the TLR. ssRNA, single-stranded RNA. NS, not significant
(P = 0.11 (Pam3Cys) or 0.079 (LPS)); *P < 0.05 (Student’s t-test). (b) Immunoblot analysis
of TRAF6 in wild-type and Nlrc3−/− peritoneal macrophages. (c) Expression of Nlrc3 in
wildtype peritoneal macrophages stimulated for 8 h ex vivo with LPS, followed by
replacement of medium and further culture for a total of 120 h (presented as in Fig. 4c). (d)
Expression of Nlrc3 in wild-type peritoneal cells after intraperitoneal challenge with LPS
(presented as in Fig. 4c). (e) Immunoblot analysis of TRAF6 in wild-type and Nlrc3−/−
peritoneal macrophages left untreated (−) or stimulated for 24 h with LPS (+). Data are from
at least four independent experiments (a; average and s.e.m.), three experiments (c; error
bars, s.e.m.) or two experiments with at least four mice (d; average and s.e.m.) or are
representative of at least three experiments (b) or three independent experiments (e).
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Nlrc3−/− macrophages have more K63-linked ubiquitination of TRAF6 and activation of
NF-κB. (a) Immunoblot analysis of K63-linked ubiquitination (K63-Ub) of endogenous
TRAF6 immunoprecipitated from wild-type and Nlrc3−/− bone marrow macrophages
stimulated with LPS (top two bots), and immunoblot analysis of TRAF6 and IκBα in those
same cells without immunoprecipitation (below). IP ctl Nlrc3−/− (far left), unstimulated
Nlrc3−/− cells (control). (b) Confocal microscopy of p65 in wild-type and Nlrc3−/−
macrophages before (UT) and after (LPS) 15 min of stimulation with LPS. Original
magnification, ×630. Bottom, quantification of nuclear p65 in the images above (from at
least three fields of view with at least 100 cells per sample). (c–e) Immunoblot analysis of
phosphorylated p65 (c), the degradation of total IκBα (d) and phosphorylated Erk, Jnk and
p38 (e) in wild-type and Nlrc3−/− macrophages stimulated for various times (above lanes)
with LPS. Data are representative of at least three independent experiments (error bars (b),
s.e.m.).
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Nlrc3−/− mice have a more severe reaction to sublethal challenge with LPS than do wild-
type mice. (a, b) Change in body temperature (a) and weight (b) over time in wild-type and
Nlrc3−/− mice challenged with LPS (4.5 mg per kg body weight). *P < 0.05 (one-way
analysis of variance with Newman-Kuels post-test). (c) TNF, IL-6 and IL-1β in the serum of
wild-type and Nlrc3−/− mice at 24 or 48 h after LPS challenge as in a. *P < 0.01 (Student’s
t-test). (d) TNF and IL-6 in the peritoneum (PL) of wild-type and Nlrc3−/− mice at 24 or 48
h after LPS challenge as in a. *P < 0.005 (Student’s t-test). (e) Real-time PCR analysis of
Il6, Tnf and Il1b in wild-type and Nlrc3−/− peritoneal cells 24 h after LPS challenge as in a
(presented as in Fig. 4c). (f) Monocytes (Mo), lymphocytes (Ly), neutrophils (N), mast cells
(MC) and eosinophils (Eo) in peritoneal lavage fluid of wild-type and Nlrc3−/− mice 24 h
after LPS challenge as in a, assessed by a differential Wright-Giemsa staining assay and
presented relative to the total peritoneal cell population (in three fields). *P < 0.05
(Student’s t-test). Data are representative of at least four independent experiments (a, b;
average of at least 12 mice per group), five experiments (c, d; mean and s.e.m. of 9–16
mice), at least four experiments (e; error bars, s.e.m.) or three experiments (f; error bars,
s.e.m.).
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Table 1
Minor and major TRAF2-binding motifs and TRAF6-binding motifs in NLR proteins
NLR NCBI reference sequence TRAF2 (minor) TRAF2 (major) TRAF6
CIITA NP_000237.2 57 (AGEE); 674 (TLQE); 910 (AAEE); 1115 (SVQE) 29 (PLEGGY); 337
(PVEQFY)
NAIP NP_004527.2 232 (SSEE); 276 (AYEE); 448 (PVQE); 746 (AFQE);
1068 (AEQE); 1219 (PDEE)
Nod1 AAD43922.1 479 (TQEE)
Nod2 NP_071445.1 106 (AAQE); 1024 (SLEE)
NLRC3 NP_849172.2 457 (SLQE); 582 (SVEE)
NLRC4 AAH31555.1 445 (SFQE); 541 (TEQE)
NLRC5 NP_115582.3 516 (SLQE); 1210 (SNEE); 1429 (PRQE); 1607
(SLEE)
273 (PSELLF)
NLRP1 AAH51787.1 994 (PTEGLD) 169 (PSQE); 1047 (SHEE) 1247 (PEEVTF)
NLRP2 AAH39269.1 612 (SQEE)
NLRP3 NP_004886.3 112 (SIEE); 179 (SQQE); 524 (TFQE); 1020 (TLQE) 689 (PKEEEE)
NLRP4 NP_604393.2 51 (SREE); 232 (SFEE); 971 (TAEE) 284 (PKELRD)
NLRP5 NP_703148.4 244 (AEEE); 706 (SFQE)
NLRP6 NP_612202.1 25 (ALEE); 158 (APEE); 165 (PAEE); 501 (SFQE);




NLRP7 AAI09126.1 505 (SGEE); 578 (SQEE)
NLRP8 NP_789781.2 49 (SHEE); 497 (AGEE); 509 (TFQE)
NLRP9 NP_789790.2 88 (AQEE); 499 (STEE); 964 (SVEE)
NLRP10 NP_789791.1 143 (PEQE); 257 (PFEE); 316 (SEEE); 612 (PKEE)
NLRP11 NP_659444.2 48 (TKEE)
NLRP12 NP_653288.1 202 (PDEE); 516 (SFQE)
NLRP13 NP_789780.2 38 (PQQLMD) 117 (PTQE); 140 (PNQE); 163 (PNQE); 295 (PIEE);
538 (SFQE); 645 (SQEE)
NLRP14 NP_789792.1 91 (AKEE); 243 (PIEE); 267 (AFEE); 334 (AREE) 67 (PGEKAW)
NLRX1 AAI10891.1 672 (PSELLD) 94 (PREE); 459 (TEEE); 496 (AMQE) 262 (PEEPQE); 611
(PDEPPE)
Sequences of TRAF-binding motifs in various NLR proteins; numbers before sequences (in one-letter code) correspond to first amino acid of
motif. P-X-(Q/E)-X-X-D is the minor TRAF2-binding motif (and is the TRAF6-binding motif if third residue is Glu (E)); (P/S/A/T)-X-(Q/E)-E is
the major TRAF2-binding motif; and P-X-E-X-X-aromatic (F/W/Y)-acidic (D/E)) is the TRAF6-binding motif (where ‘X’ indicates any amino
acid and ‘/’ indicates ‘or’). The minor TRAF2-binding motifs for NLRP1 and NLRX1 may also be TRAF6-binding motifs.
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